•Q4 2016:
-Net sales $366.5 million (+5% actual, +8% CER vs. +8% CER guidance)
-EPS $0.04; adjusted EPS $0.15 ($0.16 CER vs. $0.15-0.16 CER guidance),
adjusted EPS excl. charge $0.39 ($0.41 CER vs. $0.38 CER guidance)
•Full-year 2016:
-Net sales $1.34 billion (+4% actual, +6% CER vs. +6-7% CER guidance)
-EPS $0.34; adjusted EPS $0.87 ($0.90 CER vs. $0.87-0.88 CER guidance),
adjusted EPS excl. charge $1.11 ($1.14 CER vs $1.10-1.11 CER guidance)
-Free cash flow rises 22% to $267 million
QIAGEN reaffirms full-year 2017 outlook for 6-7% CER sales growth and adjusted EPS target before restructuring costs of $1.25-1.27 CER
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the fourth quarter and full-year 2016, delivering on goals for improvements in net sales and adjusted earnings.
"QIAGEN's performance during 2016 shows our transformation is building momentum thanks to the power of our Sample to Insight portfolio and we are moving ahead on a new growth trajectory," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. "We have strengthened our position as a global leader in molecular testing, and we expect to make significant progress in 2017."
Click here for full press release
Contacts Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 +1-240-686-2222 Dr. Sarah Fakih Associate Director Investor Relations +49-2103-29-11457 Email: ir@qiagen.com Public Relations: Dr. Thomas Theuringer Senior Director Public Relations and Digital Communications +49-2103-29-11826 +1-240-686-7425 Email: pr@qiagen.com
http://www.twitter.com/qiagen http://www.facebook.com/QIAGEN Download the QIAGEN Investor Relations App Apple: https://itunes.apple.com/us/app/qiagen-investor-relations/id1170201291?mt=8 Android: https://play.google.com/store/apps/details?id=com.theirapp.qiagen&hl=de
SOURCE QIAGEN N.V.
